The pharmaceutical company will produce the full line of its prostate cancer products, topical dermatological products, generic dermatology products and clinical supplies for future products in development in the new facility.
"Our product development efforts have grown appreciably over the last few years and we have a number of excellent products moving to commercialization," says David R. Bethune, chairman and chief executive officer. "As a result, we are broadening our manufacturing and laboratory facilities to support these and future projects."
Approximately 40% of the new building will be devoted to production with the remainder allotted for warehousing, quality assurance and laboratory work. Construction is expected to be completed by late December.
Once the building is complete, an extensive FDA certification of the plant and equipment is required, which could take up to five months.
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more inforrmation visit Asset & Logo Licensing.
